XOMA Corporation, a biotech royalty aggregator, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include PTH1R program, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; and X213, an allosteric inhibitor of prolactin action;. The company also licenses antibody discovery, optimization, and development technologies. It has research and development collaboration agreements with Novartis Vaccines and Diagnostics, Inc.; Novartis Pharma AG; Novartis International Pharmaceutical Ltd.; Rezolute, Inc.; Takeda Pharmaceutical Company Limited; and Cadila Healthcare Limited. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

IPO Year: 1986

Exchange: NASDAQ

Website: xoma.com